Media Materials

2016

10-04-2016: Medicaid Personal Care Services

In this investigative advisory, OIG identifies concerns about fraud and patient harm that build upon those outlined in a Portfolio report issued in November 2012, Medicaid Personal Care Services: Trends, Vulnerabilities, and Recommendations for Improvement.
07-13-2016: Child Care and Development Fund

The Child Care and Development Fund (CCDF) is a partnership between the Department of Health and Human Services' (HHS) Administration for Children and Families and States. CCDF provides eligible, low-income families with help paying for child care at a provider of their choice. Around 1.5 million children receive a child care subsidy from the CCDF program every month. To address fraud, waste, and abuse in the CCDF program, the Office of Inspector General (OIG) uses a multidisciplinary approach, including a rigorous program of audits, investigations, and evaluations. The OIG also is undertaking an initiative to address challenges common to HHS grant programs through in-depth, targeted efforts. This initiative focuses on internal controls, program effectiveness, and prevention of fraud, waste, and abuse in grant programs.
06-22-2016: National Health Care Fraud Takedown 2016

The Department of Health and Human Services Office of Inspector General, along with our state and federal law enforcement partners, participated in the largest health care fraud takedown in history in June 2016. Approximately 275 individuals in 30 judicial districts were charged for their alleged participation in Medicare and Medicaid fraud schemes involving about $800 million in false billings to these programs.
06-09-2016: FDA Food Recall Early Alert

OIG found that the Food and Drug Administration did not have an efficient and effective food recall initiation process that helps ensure the safety of the Nation's food supply. Specifically, FDA did not have policies and procedures to ensure that firms or responsible parties initiated voluntary food recalls promptly. This issue is a significant matter and requires FDA's immediate attention.